| Target Price | ¥1,994.10 |
| Price | ¥1,955.00 |
| Potential |
2.00%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Olympus 2027 .
The average Olympus target price is ¥1,994.10.
This is
2.00%
register free of charge
¥3,465.00
77.24%
register free of charge
¥1,818.00
7.01%
register free of charge
|
|
| A rating was issued by 17 analysts: 8 Analysts recommend Olympus to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Olympus stock has an average upside potential 2027 of
2.00%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 1,010.68 | 1,094.82 |
| 1.34% | 8.33% | |
| EBITDA Margin | 18.52% | 20.04% |
| 16.94% | 8.22% | |
| Net Margin | 6.75% | 9.52% |
| 42.92% | 41.14% |
14 Analysts have issued a sales forecast Olympus 2027 . The average Olympus sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Olympus EBITDA forecast 2027. The average Olympus EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Olympus Analysts have issued a net profit forecast 2027. The average Olympus net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 61.32 | 98.02 |
| 40.45% | 59.85% | |
| P/E | 19.98 | |
| EV/Sales | 2.17 |
14 Analysts have issued a Olympus forecast for earnings per share. The average Olympus EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


